本文内容已经过同行评议,以优先出版方式在线发表,可作为有效引用数据。由于优先发表的内容尚未完成规范的编校流程,《中华外科杂志》不保证其数据与正式版内容的完全一致。 【引用本文】郭惠明,魏培坚.梗阻性肥厚型心肌病外科治疗的挑战与未来[J].中华外科杂志,2023,61(3):181-186. 梗阻性肥厚型心肌病外科治疗的挑战与未来 经过60余年的发展,随着对梗阻性肥厚型心肌病的病理生理学理解的加深,室间隔心肌切除术的应用范围和切除厚度明显增加,术中同时处理异常的二尖瓣装置,成为新的标准治疗方案。由于该术式难度高,能够常规开展的中心不多,且新型药物陆续研发,介入治疗技术不断进步,梗阻性肥厚型心肌病外科治疗的发展面临诸多挑战。同时,一代代心血管外科医师为改进和推广室间隔心肌切除术而不断尝试与创新,一方面改进器械和改善术野,另一方面利用先进技术完善手术规划,成为外科治疗发展的重要方向。室间隔心肌切除术的远期疗效已获得广泛证实,外科医师唯有不畏挑战,共同推动梗阻性肥厚型心肌病外科治疗接续发展,以守卫人民生命健康。 肥厚型心肌病是最常见的常染色体显性遗传心肌病,发病率为0.2%~0.5%[1]。对于存在左心室流出道梗阻的梗阻性肥厚型心肌病(hypertrophic cardiomyopathy,HCM),Cleland于1958年尝试经主动脉入路切除部分肥厚的室间隔心肌,但切除的心肌十分有限[2]。此后60余年间,经过一代代心血管外科医师的不断改进,室间隔心肌切除术(septal myectomy,SM)成为梗阻性HCM的标准外科治疗术式,指南中一直推荐将其作为药物治疗无效梗阻性HCM患者的首选治疗方式[3, 4, 5]。近年来,该术式取得了明显进展,同时也面临着诸多挑战。 一、外科治疗面临的挑战 二、外科治疗的发展希望 三、结语 参考文献 (在框内滑动手指即可浏览) [1]SemsarianC, InglesJ, MaronMS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2015, 65(12):1249-1254. DOI: 10.1016/j.jacc.2015.01.019. [2]GoodwinJF, HollmanA, ClelandWP, et al. Obstructive cardiomyopathy simulating aortic stenosis[J]. Br Heart J, 1960, 22(3):403-414. DOI: 10.1136/hrt.22.3.403. [3]GershBJ, MaronBJ, BonowRO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2011, 124(24):2761-2796. DOI: 10.1161/CIR.0b013e318223e230. [4]ElliottPM, AnastasakisA, BorgerMA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2014,35(39):2733-2779. DOI:10.1093/eurheartj/ehu284. [5]OmmenSR, MitalS, BurkeMA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2020, 142(25):e533-e557. DOI: 10.1161/CIR.0000000000000938. [6]Weissler-SnirA, AdlerA, RakowskiH. MV surgery as adjunct to surgical myectomy for obstructive HCM: less is more than enough[J]. J Am Coll Cardiol, 2016, 68(14):1505-1508. DOI: 10.1016/j.jacc.2016.04.070. [7]HongJH, SchaffHV, NishimuraRA, et al. Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures[J]. J Am Coll Cardiol, 2016,68(14):1497- 1504. DOI: 10.1016/j.jacc.2016.07.735. [8]HolstKA, HansonKT, OmmenSR, et al. Septal myectomy in hypertrophic cardiomyopathy: national outcomes of concomitant mitral surgery[J]. Mayo Clin Proc, 2019, 94(1):66-73. DOI: 10.1016/j.mayocp.2018.07.022. [9]HodgesK, RivasCG, AguileraJ, et al. Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center[J]. J Thorac Cardiovasc Surg, 2019, 157(6):2289-2299. DOI: 10.1016/j.jtcvs.2018.11.148. [10]Bogachev-ProkophievA, AfanasyevAV, ZheleznevS, et al. Septal myectomy with vs without subvalvular apparatus intervention in patients with hypertrophic obstructive cardiomyopathy: a prospective randomized study[J]. Semin Thorac Cardiovasc Surg, 2019, 31(3):424-431. DOI: 10.1053/j.semtcvs.2019.01.011. [11]唐亚捷, 宋云虎, 邓隆, 等. 扩大心肌切除术对消除肥厚型梗阻性心肌病二尖瓣反流的效果分析[J].中国循环杂志, 2018, 33(6):585-590. DOI:10.3969/j.issn.1000-3614.2018.06.014. [12]谢小霜, 范洁. 左束支解剖结构对左束支区域起搏的临床指导意义[J].心血管病学进展, 2020, 41(11):1196-1198, 1208. DOI: 10.16806/j.cnki.issn.1004-3934.2020.11.022. [13]CuiH, SchaffHV, NishimuraRA, et al. Conduction abnormalities and long-term mortality following septal myectomy in patients with obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2019, 74(5):645-655. DOI: 10.1016/j.jacc.2019.05.053. [14]赵兰婷, 吴永健. 左束支传导阻滞临床研究进展[J].医学综述,2015, 21(18):3364-3367. DOI: 10.3969/j.issn.1006-2084.2015.18.037. [15]ZhengR, DongY, WuS, et al. Conduction system pacing following septal myectomy: insights into site of conduction block[J]. J Cardiovasc Electrophysiol, 2022, 33(3):437-445. DOI: 10.1111/jce.15362. [16]SpiritoP, FerrazziP. We need more high-volume myectomy centres in Europe[J]. Eur J Heart Fail, 2018, 20(2):406-408. DOI: 10.1002/ejhf.1061. [17]KimLK, SwaminathanRV, LooserP, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003-2011[J]. JAMA Cardiol, 2016, 1(3):324-332. DOI: 10.1001/jamacardio.2016.0252. [18]MaronBJ, DearaniJA, MaronMS, et al. Why we need more septal myectomy surgeons: an emerging recognition[J]. J Thorac Cardiovasc Surg, 2017, 154(5):1681-1685. DOI: 10.1016/j.jtcvs.2016.12.038. [19]PolancoAR, D′AngeloA, SheaN, et al. Impact of septal myectomy volume on mitral-valve replacement rate in hypertrophic cardiomyopathy patients[J]. Cardiology, 2020, 145(3):161-167. DOI: 10.1159/000504215. [20]OlivottoI, OreziakA, Barriales-VillaR, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2020, 396(10253):759-769. DOI:10.1016/S0140-6736(20)31792-X. [21]DesaiMY, OwensA, GeskeJB, et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy[J]. J Am Coll Cardiol, 2022, 80(2):95-108. DOI: 10.1016/j.jacc.2022.04.048. [22]MaronBJ. Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy[J]. Circulation, 2007, 116(2):196-206. DOI:10.1161/CIRCULATIONAHA.107.691378. [23]罗晓亮, 袁建松, 杨伟宪. 中国医学科学院阜外医院经皮室间隔心肌消融术临床操作规范[J].中国分子心脏病学杂志, 2021, 21(3):3913-3917. DOI:10.16563/j.cnki.1671-6272.2021.06.001. [24]ArévalosV, Rodríguez-AriasJJ, BrugalettaS, et al. Alcohol septal ablation: an option on the rise in hypertrophic obstructive cardiomyopathy[J]. J Clin Med, 2021, 10(11):2276. DOI: 10.3390/jcm10112276. [25]魏培坚, 吴宏祥, 谭桐, 等. 全胸腔镜经二尖瓣行室间隔心肌切除术治疗室间隔酒精消融术后复发左心室流出道梗阻[J].中国胸心血管外科临床杂志, 2022[2022-09-15]. https://kns.cnki.net/kcms/detail/detail.aspx?FileName=ZXYX20220909000&DbName=CAPJ2022.[published online ahead of print September 14, 2022]. [26]ChoYH, QuintanaE, SchaffHV, et al. Residual and recurrent gradients after septal myectomy for hypertrophic cardiomyopathy-mechanisms of obstruction and outcomes of reoperation[J]. J Thorac Cardiovasc Surg, 2014, 148(3):909-916. DOI: 10.1016/j.jtcvs.2014.05.028. [27]JiQ, WangYL, YangY, et al. Mini-invasive surgical instruments in transaortic myectomy for hypertrophic obstructive cardiomyopathy: a single-center experience with 168 cases[J]. J Cardiothorac Surg, 2021, 16(1):25. DOI: 10.1186/s13019-021-01403-3. [28]刘方钰,季强,王毓琳,等.梗阻性肥厚型心肌病的外科治疗:单中心5年421例经验总结[M].中华外科杂志,2023,61(3):201-208.DOI:10.3760/cma.j.cn112139-20221129-00505. [29]FangJ, WangR, LiuH, et al. Transapical septal myectomy in the beating heart via a minimally invasive approach: a feasibility study in swine[J]. Interact Cardiovasc Thorac Surg, 2020, 30(2):303-311. DOI: 10.1093/icvts/ivz249. [30]CasselmanF, VanermenH. Idiopathic hypertrophic subaortic stenosis can be treated endoscopically[J]. J Thorac Cardiovasc Surg, 2002, 124(6):1248-1249. DOI: 10.1067/mtc.2002.125644. [31]KhalpeyZ, KorovinL, ChitwoodWR, et al. Robot-assisted septal myectomy for hypertrophic cardiomyopathy with left ventricular outflow tract obstruction[J]. J Thorac Cardiovasc Surg, 2014, 147(5):1708-1709. DOI: 10.1016/j.jtcvs.2013.12.017. [32]WehmanB, GhoreishiM, FosterN, et al. Transmitral septal myectomy for hypertrophic obstructive cardiomyopathy[J]. Ann Thorac Surg, 2018, 105(4):1102-1108. DOI: 10.1016/j.athoracsur.2017.10.045. [33]Heredia CambraT, Doñate BertolínL, Bel MínguezAM, et al. Experience, outcomes and impact of delayed indication for video-assisted wide septal myectomy in 69 consecutive patients with hypertrophic cardiomyopathy[J]. Eur J Cardiothorac Surg, 2013, 44(2):e149-e155. DOI: 10.1093/ejcts/ezt050. [34]ParkSJ, ParkBJ, KimTH, et al. Videoscope-assisted transaortic myectomy in patients with hypertrophic cardiomyopathy with complex left ventricular anatomy[J]. J Card Surg, 2021, 36(9):3283-3287. DOI:10.1111/jocs.15763. [35]WangS, WangZ, ZhouB, et al. Minimally invasive right infra-axillary thoracotomy for transaortic septal myectomy[J]. J Card Surg, 2022, 37(7):2197-2201. DOI: 10.1111/jocs.16546. [36]崔勇,王树伟,周冰,等.胸腔镜辅助右腋下小切口经主动脉改良Morrow手术60例临床分析[M].中华外科杂志,2023,61(3):209-214.DOI:10.3760/cma.j.cn112139-20221014-00439. [37]马介旭, 郭惠明, 刘健, 等. 全腔镜下经二尖瓣改良扩大Morrow术同期行二尖瓣成形术1例[J].岭南心血管病杂志, 2019, 25(6):709-712. DOI:10.3969/j.issn.1007-9688.2019.06.26. [38]TangY, ZhuW, LiuJ, et al. Thoracoscopic transmitral myectomy for an anatomically complex case with midventricular obstruction[J]. Ann Thorac Surg, 2021, 112(4):e283-e286. DOI:10.1016/j.athoracsur.2020.08.092. [39]魏培坚,刘健,谭桐,等.胸腔镜经二尖瓣室间隔心肌切除术治疗左心室中部梗阻的肥厚型心肌病的早期效果[M].中华外科杂志,2023,61(3):215-220.DOI:10.3760/cma.j.cn112139-20220918-00399. [40]SpiritoP, BinacoI, PoggioD, et al. Role of preoperative cardiovascular magnetic resonance in planning ventricular septal myectomy in patients with obstructive hypertrophic cardiomyopathy[J]. Am J Cardiol, 2019, 123(9):1517-1526. DOI: 10.1016/j.amjcard.2019.01.041. [41]YangDH, KangJW, KimN, et al. Myocardial 3-dimensional printing for septal myectomy guidance in a patient with obstructive hypertrophic cardiomyopathy[J]. Circulation, 2015, 132(4):300-301. DOI:10.1161/CIRCULATIONAHA.115.015842. [42]TakayamaH, YuSN, SorabellaR, et al. Virtual septal myectomy for preoperative planning in hypertrophic cardiomyopathy[J]. J Thorac Cardiovasc Surg, 2019, 158(2):455-463. DOI: 10.1016/j.jtcvs.2018.10.138. [43]HermsenJL, YangR, BurkeTM, et al. Development of a 3-D printing-based cardiac surgical simulation curriculum to teach septal myectomy[J]. J Thorac Cardiovasc Surg, 2018, 156(3):1139-1148. DOI: 10.1016/j.jtcvs.2017.09.136. [44]DesaiMY, Tower-RaderA, SzpakowskiN, et al. Association of septal myectomy with quality of life in patients with left ventricular outflow tract obstruction from hypertrophic cardiomyopathy[J]. JAMA Netw Open, 2022, 5(4):e227293.DOI: 10.1001/jamanetworkopen.2022.7293. [45]NguyenA, SchaffHV, NishimuraRA, et al. Survival after myectomy for obstructive hypertrophic cardiomyopathy: what causes late mortality?[J]. Ann Thorac Surg, 2019, 108(3):723-729. DOI: 10.1016/j.athoracsur.2019.03.026. [46]CuiH, SchaffHV, WangS, et al. Survival following alcohol septal ablation or septal myectomy for patients with obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2022, 79(17):1647-1655. DOI:10.1016/j.jacc.2022.02.032. |
|